Quayle Munro is pleased to announce that it has advised Dove Medical Press, an Open Access (“OA”) publisher, on its sale to Taylor & Francis Group, a leading publisher of specialist academic books and journals and part of Informa PLC.
Dove Medical Press publishes primarily in the Health Sciences, with additional content in Science and Technology. Since its foundation in 2003, it has steadily built up an attractive portfolio of high quality OA journals including OncoTargets and Therapy (IF 2.612), Clinical Epidemiology (IF 7.056), International Journal of Chronic Obstructive Pulmonary Disease (IF 3.157), International Journal of Nanomedicine (IF 4.3). 86 of the journals are indexed in Clarivate’s Web of Science and 61 in PubMed.
Philip Smith, Director at Dove Medical Press, said: “We are delighted by the outcome of this transaction. Over the last 13 years, the aim of Dove Medical Press has been to make original, high quality medical and scientific research openly available. I believe that Taylor & Francis shares this vision, and for that reason, I am confident that they are best placed to nurture and grow the Dove journal portfolio. We are very appreciative of Quayle Munro’s strategic guidance and execution capability.”
Julian Moore, Managing Director at Quayle Munro, said: “We are very pleased to have advised the shareholders of Dove Medical Press on this transaction. We believe that Taylor & Francis is a great fit for the company.”
This transaction continues Quayle Munro’s recent work in the Publishing and Academic Research sectors. Quayle Munro has completed transactions involving Informa, RELX Group, Springer Nature and Thomson Reuters (Clarivate).